Anaptysbio Total Assets Growth & History (ANAB)
Anaptysbio's total assets was $364.4M for fiscal 2025.
View full Anaptysbio company overviewAnaptysbio annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $364.4M | −$119.4M | −24.69% |
| 2024 | 2024-12-31 | $483.8M | $31.4M | +6.95% |
| 2023 | 2023-12-31 | $452.4M | −$158.0M | −25.88% |
| 2022 | 2022-12-31 | $610.4M | −$32.7M | −5.08% |
| 2021 | 2021-12-31 | $643.1M | $226.5M | +54.38% |
| 2020 | 2020-12-31 | $416.6M | −$18.6M | −4.28% |
| 2019 | 2019-12-31 | $435.2M | −$73.8M | −14.50% |
| 2018 | 2018-12-31 | $509.0M | $179.6M | +54.54% |
| 2017 | 2017-12-31 | $329.4M | $267.2M | +429.69% |
| 2016 | 2016-12-31 | $62.2M | — | — |
Anaptysbio quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $329.7M | −$92.4M | −21.89% |
| Q4 2025 | 2025-12-31 | $364.4M | −$119.4M | −24.69% |
| Q3 2025 | 2025-09-30 | $353.1M | −$140.3M | −28.44% |
| Q2 2025 | 2025-06-30 | $335.3M | −$92.1M | −21.56% |
| Q1 2025 | 2025-03-31 | $422.1M | $16.2M | +4.00% |
| Q4 2024 | 2024-12-31 | $483.8M | $31.4M | +6.95% |
| Q3 2024 | 2024-09-30 | $493.4M | $6.1M | +1.25% |
| Q2 2024 | 2024-06-30 | $427.4M | −$89.7M | −17.35% |
| Q1 2024 | 2024-03-31 | $405.8M | −$146.0M | −26.45% |
| Q4 2023 | 2023-12-31 | $452.4M | −$158.0M | −25.88% |
| Q3 2023 | 2023-09-30 | $487.3M | −$131.2M | −21.21% |
| Q2 2023 | 2023-06-30 | $517.1M | −$86.7M | −14.37% |
| Q1 2023 | 2023-03-31 | $551.8M | −$73.4M | −11.74% |
| Q4 2022 | 2022-12-31 | $610.4M | −$32.7M | −5.08% |
| Q3 2022 | 2022-09-30 | $618.5M | $194.2M | +45.76% |
| Q2 2022 | 2022-06-30 | $603.8M | $177.3M | +41.56% |
| Q1 2022 | 2022-03-31 | $625.2M | $228.8M | +57.70% |
| Q4 2021 | 2021-12-31 | $643.1M | $226.5M | +54.38% |
| Q3 2021 | 2021-09-30 | $424.3M | $39.6M | +10.29% |
| Q2 2021 | 2021-06-30 | $426.6M | $24.8M | +6.18% |
| Q1 2021 | 2021-03-31 | $396.4M | −$27.8M | −6.56% |
| Q4 2020 | 2020-12-31 | $416.6M | −$18.6M | −4.28% |
| Q3 2020 | 2020-09-30 | $384.8M | −$66.8M | −14.78% |
| Q2 2020 | 2020-06-30 | $401.7M | −$78.4M | −16.33% |
| Q1 2020 | 2020-03-31 | $424.2M | −$70.0M | −14.16% |
| Q4 2019 | 2019-12-31 | $435.2M | −$73.8M | −14.50% |
| Q3 2019 | 2019-09-30 | $451.5M | −$71.6M | −13.69% |
| Q2 2019 | 2019-06-30 | $480.1M | $174.1M | +56.90% |
| Q1 2019 | 2019-03-31 | $494.2M | $179.4M | +56.98% |
| Q4 2018 | 2018-12-31 | $509.0M | $179.6M | +54.54% |
| Q3 2018 | 2018-09-30 | $523.1M | $401.2M | +328.98% |
| Q2 2018 | 2018-06-30 | $306.0M | $175.6M | +134.66% |
| Q1 2018 | 2018-03-31 | $314.8M | $183.7M | +140.13% |
| Q4 2017 | 2017-12-31 | $329.4M | $267.2M | +429.69% |
| Q3 2017 | 2017-09-30 | $121.9M | — | — |
| Q2 2017 | 2017-06-30 | $130.4M | — | — |
| Q1 2017 | 2017-03-31 | $131.1M | — | — |
| Q4 2016 | 2016-12-31 | $62.2M | — | — |
Anaptysbio total assets trends
Over the last five fiscal years, Anaptysbio's total assets decreased from $416.6M to $364.4M, a change of −$52.2M. The latest reported quarter, Q1 2026, shows $329.7M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anaptysbio source filings ↗